NDA 200890 · Sandoz
Isopto Carpine
Pilocarpine Hydrochloride · Ophthalmic
Priority reviewLast checked: Nov 19, 2026Latest source record: Feb 12, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Jun 22, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
57
21 Phase 3, 2 recruiting
FAERS reports
1,211
642 serious, 34 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 19, 2020.
Pilocarpine hydrochloride ophthalmic solution is indicated for the: Pilocarpine hydrochloride ophthalmic solution is a muscarinic cholinergic agonist indicated for: • The reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1.1 ) • The management of acute angle-closure glaucoma. ( 1.2 ) • The prevention of postoperative elevated IOP associated with laser surgery. ( 1.3 ) • The induction of miosis. ( 1.4 ) 1.1 Reduction of Elevated Intraocular Pressure (IOP) in Patients With Open-Angle Glaucoma or Ocular Hypertension . 1.2 Management of Acute Angle-Closure Glaucoma . 1.3 Prevention of Postoperative Elevated IOP Associated With Laser Surgery . 1.4 Induction of Miosis .
Mechanism: Pilocarpine hydrochloride is a direct acting cholinergic parasympathomimetic agent which acts through direct stimulation of muscarinic receptors and smooth muscle such as the iris and secretory glands. Pilocarpine contracts the ciliary muscle, causing increased tension on the scleral spur and opening of the trabecular meshwork spaces to facilitate outflow of aqueous humor. Outflow resistance is reduced, lowering IOP. Pilocarpine also produces miosis through contraction of the iris sphincter muscle. Miosis relieves appositional angle narrowing and closure, which lowers IOP in certain types of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 22, 2010 Original approval · Type 3 - New Dosage Form · priority review LabelReviewSummary Review
3 products under this application
- ISOPTO CARPINE · PILOCARPINE HYDROCHLORIDE 4% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
- ISOPTO CARPINE · PILOCARPINE HYDROCHLORIDE 1% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
- ISOPTO CARPINE · PILOCARPINE HYDROCHLORIDE 2% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Pilocarpine" as an intervention, any sponsor and status, largest first.
- A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With PresbyopiaPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT03857542 · 427 participants · Start Mar 1, 2019 · Primary completion Sep 10, 2020
Drug: Pilocarpine HCl Ophthalmic Solution · For: Presbyopia
Sites: Dothan, Alabama; Prescott, Arizona; Sun City, Arizona · 35 sites in all
- Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OABPivotal-lookingCompleted
SK Chemicals Co., Ltd.Industry
NCT02485067 · 384 participants · Start Jan 2015 · Primary completion Jul 2016
Drug: THVD-201; Placebo(For THVD-201) and 2 more · For: Overactive Bladder
Sites: Busan, South Korea; Cheonan, South Korea; Gwangju, South Korea · 16 sites in all
- Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With PresbyopiaPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT05646719 · 333 participants · Start Dec 22, 2022 · Primary completion Oct 11, 2023
Drug: Phentolamine Opthalmic Solution 0.75%; Low dose pilocarpine · For: Presbyopia
Sites: Phoenix, Arizona; Azusa, California; Newport Beach, California · 26 sites in all
- Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With PresbyopiaPivotal-lookingStatus unknown
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT06451666 · 330 participants (planned) · Start Jun 30, 2024 · Primary completion Nov 30, 2025
Drug: Pilocarpine HCl Ophthalmic Solution; Vehicle · For: Presbyopia
- Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With PresbyopiaPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT03804268 · 323 participants · Start Dec 21, 2018 · Primary completion Oct 31, 2019
Drug: Pilocarpine HCl Ophthalmic Solution · For: Presbyopia
Sites: Chandler, Arizona; Scottsdale, Arizona; Beverly Hills, California · 36 sites in all
- An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)Pivotal-lookingCompleted
Orasis Pharmaceuticals Ltd.Industry
NCT04599933 · 309 participants · Start Oct 18, 2020 · Primary completion Feb 11, 2022
Drug: CSF-1; Vehicle · For: Presbyopia
Sites: Sun City, Arizona; Glendale, California; Los Angeles, California · 17 sites in all
- An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)Pivotal-lookingCompleted
Orasis Pharmaceuticals Ltd.Industry
NCT04599972 · 304 participants · Start Oct 26, 2020 · Primary completion Jan 21, 2022
Drug: CSF-1; Vehicle · For: Presbyopia
Sites: Chandler, Arizona; Mesa, Arizona; Phoenix, Arizona · 18 sites in all
- The International Collaborative Exfoliation Syndrome Treatment StudyPivotal-lookingStatus unknown
The New York Eye & Ear InfirmaryAcademic, hospital or other
NCT00804115 · 277 participants · Start Aug 2000 · Primary completion Sep 2007
Drug: Latanoprost with Pilocarpine vs Timolol or Cosopt · For: Exfoliation Syndrome; Glaucoma; Ocular Hypertension
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective132
- headache97
- fatigue96
- pain96
- eye pain90
- dyspnoea85
- nausea77
- dizziness75
- diarrhoea74
- cough68
- fall67
- off label use67
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 20 |
| 2006 | 6 |
| 2007 | 5 |
| 2008 | 15 |
| 2009 | 35 |
| 2010 | 43 |
| 2011 | 8 |
| 2012 | 14 |
| 2013 | 18 |
| 2014 | 15 |
| 2015 | 16 |
| 2016 | 7 |
| 2017 | 29 |
| 2018 | 40 |
| 2019 | 77 |
| 2020 | 93 |
| 2021 | 68 |
| 2022 | 119 |
| 2023 | 107 |
| 2024 | 140 |
| 2025 | 184 |
| 2026 | 135 |
Recalls
1 FDA enforcement reports for this application.
Mar 22, 2017 · Class III · Terminated
Failed Impurities/Degradation Specifications.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance.
Waring GO, Brujic M, McGee S, et al. · Clin Exp Optom 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Neurosteroids and Seizure Activity.
Miziak B, Chrościska-Krawczyk M, Czuczwar SJ · Front Endocrinol (Lausanne) 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Two decades of research towards a potential first anti-epileptic drug.
Benassi SK, Alves JGSM, Guidoreni CG, et al. · Seizure 2021 · Randomized Controlled Trial
- Systematic review and meta-analysis of differentially expressed miRNAs in experimental and human temporal lobe epilepsy.
Korotkov A, Mills JD, Gorter JA, et al. · Sci Rep 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Sweat induction using Pilocarpine microneedle patches for sweat testing in healthy adults.
Chen JY, Li S, Silva GL, et al. · J Cyst Fibros 2024 · Controlled Clinical Trial, Research Support, Non-U.S. Gov't
- Pilocarpine 1.25% efficacy for management of uncorrected presbyopia (PILE-UP study).
Saxena R, Gupta V, Velpandian T, et al. · Indian J Ophthalmol 2025 · Clinical Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.